G. Pérez-Simó

The deletion of exons 3–5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families

I. Chirivella, P. Bolufer, E. Barragán, 2013, Familial Cancer.

Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report

S. Palanca, Ó. Juan, E. Cases, 2022, Diagnostics.

Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients

S. Palanca, J. Gomez-Codina, Ó. Juan, 2022, International journal of molecular sciences.

Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital

E. Barragán, J. Aparicio, B. Laíz, 2019, Cancers.

The deletion of exons 3–5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families

I. Chirivella, P. Bolufer, E. Barragán, 2013, Familial Cancer.

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital

S. Palanca, J. Gomez-Codina, Ó. Juan, 2023, Cancers.